stock-mb-logo-androidstock-mb-logo-ios
Stock Screener App
Gratuito - Play StoreApp Store
InstallareInstallare
logo
  • Nasdaq
  • Dow
  • S&P 500
Replimune Group IncREPL
$19.4910.68%1.88
Pre-mercato: 19.62+0.13 +0.67%

Replimune Group Inc (REPL)

Date: 2026-11-02 16:00O: 17.75H: 19.68L: 17.67C: 19.49Vol: 7.725M
Precedente Chiudi:
$17.61
Aprire:
$17.75
Volume 24 ore:
7,725,237
Volume relativo:
2.05
Capitalizzazione di mercato:
$1.85B
Reddito:
-
Utile/perdita netta:
-$313.94M
Rapporto P/E:
-
EPS:
-$3.51
Flusso di cassa netto:
-$284.57M
1W Prestazione:
+49.35%
1M Prestazione:
+49.12%
6M Prestazione:
+679.60%
1Y Prestazione:
+109.46%
Intervallo 1D:
$0.00$0.00
Intervallo di 1 settimana:
$12.50$19.68
Portata 52W:
$1.50$19.68

Profilo aziendale di Replimune Group Inc (REPL)

Nome
Replimune Group Inc
Settore
Healthcare
Industria
Biotechnology
Telefono
(781) 222-9600
Indirizzo
500 UNICORN PARK, WOBURN, MA, USA
Dipendente
465
X
@Replimune
Prossima data di guadagno
null
Ultimi documenti SEC
SEC
Discussioni di REPL su X
X

 

Cap. di mercato

 

Reddito

 

Reddito netto

 

Flusso di cassa

 

EPS

 

Replimune Group Inc Azioni (REPL) Upgrade e downgrade

DataAzioneAnalistaModifica della valutazione
2026-08-07AggiornamentoWedbushNeutral → Outperform
2026-08-04AggiornamentoLeerink PartnersMarket Perform → Outperform
2026-07-31AggiornamentoCantor FitzgeraldNeutral → Overweight
2026-07-31AggiornamentoWedbushNeutral → Outperform

Replimune Group Inc Azioni (REPL) Dati Finanziari

PeriodoAndamentoFY 2026FY 2025FY 2024FY 2023FY 2022
Data di fine periodo2026-03-312025-03-312024-03-312023-03-312022-03-31
Revenue USD (M)--0.000.000.00
Research and development USD (M)221.18189.45174.96126.5379.55
Operating expenses USD (M)319.92261.63234.77177.08118.31
Operating income USD (M)-319.92-261.63-234.77-177.08-118.31
Income before tax USD (M)-314.49-246.83-215.39-174.00-118.04
Income tax expense USD (M)-0.550.470.410.290.00
Net income USD (M)-313.94-247.30-215.79-174.28-118.04
Basic EPS USD/shares-3.38-3.07-3.24-2.99-2.26
Diluted EPS USD/shares-3.38-3.07-3.24-2.99-2.26
Basic weighted shares shares (M)92.8080.5666.5758.2152.21
Diluted weighted shares shares (M)92.8080.5666.5758.2152.21
Selling, general and administrative USD (M)98.74----

Replimune Group Inc Azioni (REPL) insider trading

  • Kapil DhingraNov 02 '26
    Director
    Transazione
    Proposed Sale
    Costo
    $17.75
    #Azioni
    16,500
    Valore ($)
    292,875
    #Azioni Totale
    0
  • VELEKA PEEPLES-DYEROct 30 '26
    Director
    Transazione
    Proposed Sale
    Costo
    $16.72
    #Azioni
    10,000
    Valore ($)
    167,232
    #Azioni Totale
    0
  • VELEKA PEEPLES-DYEROct 28 '26
    Director
    Transazione
    Proposed Sale
    Costo
    $12.90
    #Azioni
    12,000
    Valore ($)
    154,745
    #Azioni Totale
    0
  • Hill Emily LuisaAug 17 '26
    Chief Financial Officer
    Transazione
    Sale
    Costo
    $14.28
    #Azioni
    9,256
    Valore ($)
    132,176
    #Azioni Totale
    215,852
  • Hill Emily LuisaAug 10 '26
    Chief Financial Officer
    Transazione
    Sale
    Costo
    $12.97
    #Azioni
    11,448
    Valore ($)
    148,481
    #Azioni Totale
    225,108
  • Xynos KonstantinosAug 10 '26
    Chief Medical Officer
    Transazione
    Sale
    Costo
    $12.97
    #Azioni
    11,447
    Valore ($)
    148,468
    #Azioni Totale
    224,215
  • Schwendenman AndrewAug 10 '26
    Chief Accounting Officer
    Transazione
    Sale
    Costo
    $12.97
    #Azioni
    7,632
    Valore ($)
    98,987
    #Azioni Totale
    99,425
  • Patel SushilAug 10 '26
    Chief Executive Officer
    Transazione
    Sale
    Costo
    $12.97
    #Azioni
    39,341
    Valore ($)
    510,253
    #Azioni Totale
    708,151
  • Sarchi ChristopherJun 01 '26
    Chief Commercial Officer
    Transazione
    Sale
    Costo
    $9.24
    #Azioni
    12,000
    Valore ($)
    110,880
    #Azioni Totale
    180,962
  • Hill Emily LuisaMay 18 '26
    Chief Financial Officer
    Transazione
    Sale
    Costo
    $5.08
    #Azioni
    7,812
    Valore ($)
    39,685
    #Azioni Totale
    236,556
Commercio internoRelazioneDataTransazioneCosto#AzioniValore ($)#Azioni Totale
Kapil DhingraDirectorNov 02 '26Proposed Sale$17.7516,500292,8750
VELEKA PEEPLES-DYERDirectorOct 30 '26Proposed Sale$16.7210,000167,2320
VELEKA PEEPLES-DYERDirectorOct 28 '26Proposed Sale$12.9012,000154,7450
Hill Emily LuisaChief Financial OfficerAug 17 '26Sale$14.289,256132,176215,852
Hill Emily LuisaChief Financial OfficerAug 10 '26Sale$12.9711,448148,481225,108
Xynos KonstantinosChief Medical OfficerAug 10 '26Sale$12.9711,447148,468224,215
Schwendenman AndrewChief Accounting OfficerAug 10 '26Sale$12.977,63298,98799,425
Patel SushilChief Executive OfficerAug 10 '26Sale$12.9739,341510,253708,151
Sarchi ChristopherChief Commercial OfficerJun 01 '26Sale$9.2412,000110,880180,962
Hill Emily LuisaChief Financial OfficerMay 18 '26Sale$5.087,81239,685236,556

Replimune Group Inc Borsa (REPL) Ultime notizie

Oct 30, 2026

Replimune Group Stock Price Forecast. Should You Buy REPL? - StockInvest.us

Oct 30, 2026
Oct 29, 2026

Replimune Group, Inc. (REPL) Seasonal Returns Chart - Yahoo Finance - Yahoo! Finance Canada

Oct 29, 2026
Oct 28, 2026

Replimune Group (REPL) Launches TUDRIQEV with Early Adoption Ami - GuruFocus

Oct 28, 2026
Oct 28, 2026

Replimune: 3 Key Takeaways for Long-Term Investors - Yahoo Finance

Oct 28, 2026
Oct 28, 2026

Replimune: 3 Key Takeaways for Long-Term Investors - The Motley Fool

Oct 28, 2026
Oct 28, 2026

Replimune Group, Inc. Q2 2027 Earnings Call Summary - Yahoo Finance

Oct 28, 2026
Oct 28, 2026

Replimune Group, Inc. Stock 12‑Month Price Target Raised to $20.14, Implies 54% Upside - TradingView

Oct 28, 2026
Oct 28, 2026

Replimune Group stock hits 52-week high at 16.39 USD - Investing.com

Oct 28, 2026
Oct 28, 2026

Replimune Group, Inc. reports results for the quarter ended September 30 - Earnings Summary - TradingView

Oct 28, 2026
Oct 28, 2026

Replimune Group Q2 2027 Earnings Call Transcript - Benzinga

Oct 28, 2026
Oct 28, 2026

Q2 2027 Replimune Group, Inc. Earnings Call Transcript - GuruFocus

Oct 28, 2026
Oct 28, 2026

Replimune Group 3Q 2026: Revenue $0 Net loss $57.1M, EPS ($0.54) — 10-Q Summary - TradingView

Oct 28, 2026
Oct 28, 2026

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss - TradingView

Oct 28, 2026
Oct 28, 2026

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update - Moomoo

Oct 28, 2026
Oct 28, 2026

Replimune Reports Fiscal Second Quarter 2027 Financial Results and Provides Corporate Update - Yahoo Finance

Oct 28, 2026
Oct 28, 2026

Replimune Group (Nasdaq:REPL) - Stock Analysis - Simply Wall St

Oct 28, 2026
Oct 22, 2026

Replimune to Report the Fiscal Second Quarter 2027 Financial Results and Provide Corporate Update on October 28, 2026 - Yahoo Finance

Oct 22, 2026
Oct 20, 2026

7R8.DU interactive stock chart | Replimune Group Inc. R stock - Yahoo Finance Australia

Oct 20, 2026
Oct 20, 2026

Mestag Therapeutics Appoints Philip Astley-Sparke and Victor Sandor, M.D.C.M., to its Board of Directors - GlobeNewswire Inc.

Oct 20, 2026
Oct 20, 2026

Replimune Group Inc (7R8.DU) stock price, news, quote and history - Yahoo Finance Australia

Oct 20, 2026
Oct 18, 2026

Replimune Group Inc (7R8.DU) interactive stock chart - Yahoo Finance Australia

Oct 18, 2026
Oct 17, 2026

Replimune Group (REPL) Stock Looks Rich After A 141% Run - Yahoo Finance

Oct 17, 2026
Oct 13, 2026

Replimune Group: A Hold Until TUDRIQEV’s Commercial Potential Becomes Clear (NASDAQ:REPL) - Seeking Alpha

Oct 13, 2026
Oct 11, 2026

Why Is REPL Stock Soaring 127% After Hours Today? - Stocktwits

Oct 11, 2026
Oct 10, 2026

Replimune Group, Inc. (REPL) Options Chain - Yahoo! Finance Canada

Oct 10, 2026
Oct 10, 2026

Replimune Group, Inc. (REPL) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 10, 2026
Oct 09, 2026

Replimune Group (REPL) Launches TUDRIQEV As Its Valuation Story Comes Into Focus - Yahoo Finance

Oct 09, 2026
Oct 07, 2026

(REPL) Movement as an Input in Quant Signal Sets - Stock Traders Daily

Oct 07, 2026
Oct 06, 2026

7R8.HM Interactive Stock Chart | Replimune Group Inc. R Stock - Yahoo! Finance Canada

Oct 06, 2026
Oct 06, 2026

Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire

Oct 06, 2026
Oct 05, 2026

FDA Staff Raise Concerns On Replimune’s Skin Cancer Drug – REPL Stock Crashes 32% Today Ahead Of Advisory Meeting This Week - Stocktwits

Oct 05, 2026
Oct 05, 2026

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire

Oct 05, 2026
Oct 05, 2026

Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - WBOC TV

Oct 05, 2026
Oct 05, 2026

Replimune Group, Inc. (REPL) Options Chain - Yahoo! Finance Canada

Oct 05, 2026
Oct 04, 2026

Levi & Korsinsky Urges Replimune Group, Inc. (REPL) Shareholders to Act Before Lead Plaintiff Deadline October 5, 2026 - ACCESS Newswire

Oct 04, 2026
Oct 03, 2026

Securities Lawsuit Alert: Replimune Group, Inc. (REPL) - Contact Levi & Korsinsky Before October 5, 2026 - ACCESS Newswire

Oct 03, 2026
Oct 03, 2026

Lost Money on Replimune Group, Inc. (REPL)? Join Class Action Before October 5, 2026 - Contact Levi & Korsinsky - ACCESS Newswire

Oct 03, 2026
Oct 02, 2026

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & - GlobeNewswire

Oct 02, 2026
Oct 02, 2026

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & - GlobeNewswire

Oct 02, 2026
Oct 02, 2026

REPLIMUNE CLASS ACTION DEADLINE MONDAY: Bragar Eagel & Squire, P.C. Urgently Reminds Replimune Group Inc. Investors to Contact the Firm Seeking Lead Plaintiff Role Before October 5th - GlobeNewswire Inc.

Oct 02, 2026
Oct 02, 2026

Insiders At Replimune Group Sold US$1.6m In Stock, Alluding To Potential Weakness - Moomoo

Oct 02, 2026
Oct 02, 2026

REPL UPCOMING DEADLINE: Levi & Korsinsky Alerts Replimune Group, Inc. Stockholders of Securities Class Action - Contact the Firm - FinancialContent

Oct 02, 2026
Oct 01, 2026

Replimune Group, Inc. (7R8.MU) stock price, news, quote and history - Yahoo Finance Australia

Oct 01, 2026
Oct 01, 2026

Replimune launches melanoma therapy in US market - Investing.com

Oct 01, 2026
Oct 01, 2026

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma - FinancialContent

Oct 01, 2026
Oct 01, 2026

Replimune Announces TUDRIQEV™ Now Available in the U.S. for Advanced Melanoma - Yahoo Finance

Oct 01, 2026
Oct 01, 2026

Replimune CEO and CFO sued for allegedly mislea... - Pluang

Oct 01, 2026
Oct 01, 2026

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL - PR Newswire

Oct 01, 2026
Oct 01, 2026

SueWallSt Reminds Replimune Group, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of October 5, 2026 - REPL - TradingView

Oct 01, 2026
Sep 30, 2026

REPL Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Replimune Group, Inc. Securities Lawsuit - Contact Levi & Korsinsky - Morningstar

Sep 30, 2026

Simile a REPL

PGENPGEN$5.1425.94%VIRVIR$11.002.65%MESOMESO$14.544.09%TRAXTRAX$45.050.07%BRVEBRVE$21.042.19%ZBIOZBIO$27.622.71%